Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bimatoprost. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR known ✓ | P43088 | 8/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 1/20 | 1.00 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.80 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.63 |
| ▸ | MGLL | Q99685 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.59 |
| ▸ | SLCO2A1 | Q92959 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.59 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.57 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bimatoprost SCHEMBL1286359 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL12087441 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL10015911 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL399000 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL10071021 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL11977332 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL13187412 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL20434484 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL22364345 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL12076308 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14458 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102187-A1 | ENGINEERED VIRUS-LIKE PARTICLES COMPRISING A BASE EDITOR FOR THE TREATMENT OF GLAUCOMA, AND APPLICATIONS THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260131008-A1 | HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS | CELLA THERAPEUTICS LLC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4739302-A2 | HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS | Cella Therapeutics, LLC (US) | 2026-05-13 | — | — | EP | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| EP-4732814-A2 | METHODS AND APPARATUS FOR DELIVERY OF OCULAR IMPLANTS | ALLERGAN, INC. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-3973954-B1 | PRESERVATIVE FREE PHARMACEUTICAL COMPOSITIONS FOR OPHTHALMIC ADMINISTRATION | NTC S R L (IT) | 2026-04-22 | — | — | EP | claimed |
| EP-4727651-A1 | METHOD OF ENHANCING THE SYSTEMIC HYPOGLYCEMIC EFFECT OF TOPICALLY APPLIED INSULIN WITH THE USE OF PROSTAGLANDIN ANALOGUES: A NOVEL FIXED COMBINATION EYE DROP FORMULATION OF INSULIN AND PROSTAGLANDIN ANALOGUE FOR THE LOWERING OF BLOOD GLUCOSE LEVEL | Gosiengfiao, David Harold (PH) | 2026-04-22 | — | — | EP | claimed |
| EP-4724079-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4724839-A2 | CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS | Mediprint Ophthalmics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260090984-A1 | CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS | MEDIPRINT OPHTHALMICS INC. (US) | 2026-04-02 | — | — | US | claimed |
| WO-2002096868-A2 | PREPARATION OF 17-PHENYL- 18, 19, 20- TRINOR-PGF2A AND ITS DERIVATIVES | FINETECH LABORATORIES LTD. (IL) | 2002-12-05 | — | — | WO | claimed |
| WO-2002072105-A2 | IMPROVED PROSTANOID THERAPIES FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2002-09-19 | — | — | WO | claimed |
| US-20020103255-A1 | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension | ALCON RESEARCH, LTD. | 2002-08-01 | — | — | US | claimed |
| US-20020037887-A1 | Method for reducing intraocular pressure using indole derivatives | UNIVERSIDAD COMPLUTENSE DE MADRID (ES) | 2002-03-28 | — | — | US | claimed |
| US-20020035264-A1 | Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug | PHARMACIA & UPJOHN COMPANY | 2002-03-21 | — | — | US | claimed |
| WO-2002009702-A2 | USE OF INDOLE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR REDUCING INTRACULAR PRESSURE | INSPIRE PHARMACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | claimed |
| WO-2002005815-A1 | OPHTHALMIC FORMULATION OF A SELECTIVE CYCLOOXYGENASE-2 INHIBITORY DRUG | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-24 | — | — | WO | claimed |
| WO-2001095913-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION OF MYOPIA | SYNPHORA AB (SE) | 2001-12-20 | — | — | WO | claimed |
| WO-2001070230-A2 | COMPOUNDS WITH 5-HT ACTIVITY USEFUL FOR CONTROLLING VISUAL FIELD LOSS | ALCON, INC. (CH) | 2001-09-27 | — | — | WO | claimed |
| WO-2001070223-A1 | COMPOUNDS WITH 5-HT2 AND 5-HT1A AGONIST ACTIVITY FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2001-09-27 | — | — | WO | claimed |